What is mRNA?
Messenger RNA (mRNA) is a large family of RNA molecules that convey genetic information from DNA to the ribosome, where they specify the amino acid sequence of the protein products of gene expression.
A new class of therapeutics based on mRNA called mRNA therapeutics is currently being explored by a number of companies.
Meet Our Featured TIDES MRNA Speakers
For a full list of speakers, please visit the individual event websites.
Featured mRNA Sessions at AsiaTIDES
February 26-28, 2019 in Tokyo, Japan
Novel mRNA Immunotherapies
Robert Jabulowsky, PhD
Deputy Head of Project Management
BioNTech AG
An Introduction to mRNA Therapeutics
James Thompson, PhD
Head of CMC Project Management
Moderna Therapeutics
Effective Delivery of Therapeutic Proteins by mRNA
Nigel Horscroft, D.Phill
Vice President Development RNArt
CureVac AG
Inhibition and Degradation of Drug Targets Using bioPROTAC mRNAs – A Novel Approach with Broad Therapeutic Potential
Jeff Chang, PhD
Associate Scientist and Post Doc Fellow
MSD International GmbH (Singapore)
Optimizing Delivery of mRNA Therapeutics
Peter Lutwyche, PhD
Chief Technology Officer
Genevant Sciences Corporation
Emerging RNA Therapeutics: Delivery Approaches for mRNA, siRNA and Beyond
Shiro Akinaga, PhD
Director and CSO
AccuRna
Featured mRNA Sessions at TIDES US
May 20-23, 2019 in San Diego, CA
mRNA as a Platform Technology Ideally Suited for Individualized Therapeutics
Andreas Kuhn, PhD
Vice President, RNA Biochemistry & Manufacturing
BioNTech RNA Pharmaceuticals GmbH
Overcoming the Hurdle of Subcutaneous Delivery of mRNA in LNP to Enable Treatment of Chronic Diseases
Shalini Andersson, PhD
Senior Director, Drug Metabolism & Pharmacokinetics
AstraZeneca
Characterization of Critical Quality Attributes of mRNA, A Novel Therapeutic Modality
Huijuan Li, PhD
Head, Analytical Development
Moderna Therapeutics
Inhibition and Degradation of Drug Targets Using bioPROTAC mRNAs – A Novel Approach with Broad Therapeutic Potential
Anthony Partridge, PhD
Principal Scientist, Early Discovery Pharmacology
Merck, Sharp & Dohme
Evaluation of Modified Interferon alpha mRNA Constructs for the Treatment of Non-melanoma Skin Cancer
Markus Mandler, PhD
CSO
Accanis Biotech
Messenger RNA Therapeutics for Bone Regeneration and for Pulmonary Diseases
Christian Plank, PhD
Chief Technology Officer
Ethris GmbH
Novel mRNA Immunotherapies
Robert Jabulowsky, PhD
Deputy Head of Project Management
BioNtech AG
Nucleoside-modified mRNA Immunization against Infectious Diseases
Nobert Pardi, PhD
Research Assistant Professor of Medicine
University of Pennslyvania
mRNA Based Vaccines Expressing RSV are Immunogenic and Protective in Preclinical Models of Respiratory Syncytial Virus Infection
Andrew Geall, PhD
Vice President of Formulations, Analytics, and Chemistry
Avidity Biosciences